Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Apellis Pharmaceuticals (APLS) PT Lowered to $65 at Oppenheimer
September 10, 2021 6:58 AM EDTOppenheimer analyst Justin Kim lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $65.00 (from $80.00) while maintaining an Outperform rating.
The analyst commented, "On 9/9, Apellis reported mixed top-line results from its Phase 3 DERBY and OAKS studies (n=1,258) of pegcetacoplan in geographic... More
Apellis Pharmaceuticals (APLS) PT Lowered to $70 at Needham & Company
September 10, 2021 6:54 AM EDTNeedham & Company analyst Joseph Stringer lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $70.00 (from $85.00) while maintaining a Buy rating.
The analyst commented, "APLS announced yesterday results from the Ph3 DERBY and OAKS trials evaluating pegcetacoplan in Geographic Atrophy (GA). The... More
Apellis Pharmaceuticals (APLS) PT Lowered to $69 at BMO Capital, Overall Data 'Should Still be Enough'
September 10, 2021 6:40 AM EDTBMO Capital analyst Matthew Luchini lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $69.00 (from $89.00) while maintaining an Outperform rating, saying the "totality of data plus the unmet need in GA provides reasonable basis for approval and recommend taking advantage of current... More
Apellis Pharmaceuticals (APLS) to Resume Trading at 4:35 p.m.
September 9, 2021 4:14 PM EDTApellis Pharmaceuticals (NASDAQ: APLS) to Resume Trading at 4:35 p.m.
UPDATE: IVERIC bio (ISEE) Gains Following Results From Apellis Pharmaceuticals (APLS)
September 9, 2021 4:14 PM EDT(Updated - September 9, 2021 4:22 PM EDT)
IVERIC bio (NASDAQ: ISEE) Strength Post-Market Said Tied to Results from Apellis Pharmaceuticals (NASDAQ: APLS)
Shares Up 17%Update:
Shares Are Now Up 22%Catalyst Biosciences (NASDAQ: CBIO) Also Gained, up 15%... More